Electronic Caregiver, Inc is expanding its operations in Las Cruces, New Mexico, to establish the Rio Grande Health Technology Corridor. This initiative aims to position the region as a national hub for AI-driven healthcare infrastructure, creating high-wage jobs and integrating advanced technologies in patient care.

## Electronic Caregiver Enhances Las Cruces as National AI Healthcare Hub

Electronic Caregiver, Inc, an AI-driven healthcare infrastructure company based in Las Cruces, New Mexico, is making significant strides in its efforts to establish the Rio Grande Health Technology Corridor.

This initiative aims to position Southern New Mexico as a nationally recognized hub for AI healthcare technology, enhancing the region's reputation beyond its established strengths in national laboratories and aerospace programs.

The company's Addison Care platform represents a groundbreaking shift in healthcare delivery by integrating remote patient monitoring, TeleCare operations, and longitudinal data management.

This comprehensive approach allows for continuous healthcare engagement within patients' homes, addressing a critical need for consumer-integrated AI healthcare technology that has been historically lacking in the state.

### Building the Rio Grande Health Technology Corridor

Electronic Caregiver is actively expanding its footprint across Southern New Mexico, with plans to enhance patient monitoring, TeleCare, logistics, and technology operations from Las Cruces to Roswell over the next 12 to 18 months.

This expansion is set to create high-skill, high-wage jobs in various disciplines, including software engineering, artificial intelligence, and health network integration.

CEO Anthony Dohrmann emphasizes the importance of this initiative, stating, "Our goal is to build the first nationally and globally recognized commercial and health technology brand organically founded and headquartered in Las Cruces." He highlights the potential for growth throughout the border region, particularly given Las Cruces' proximity to El Paso, Texas.

### A National AI Healthcare Infrastructure Platform

Electronic Caregiver's platform not only facilitates daily care adherence but also enables early identification of health changes and security monitoring.

With over 100 pilot deployments and national payer approvals, the company is poised to scale its patient engagement efforts nationwide, solidifying its position within the evolving AI healthcare ecosystem.

This initiative marks a significant transition for New Mexico, which has traditionally exported scientific research and engineering talent.

The establishment of a commercial AI healthcare enterprise aims to retain and scale that talent locally, creating a robust economic framework for the region.

### Workforce Development and Collaboration with NMSU

Electronic Caregiver's commitment to workforce development is evident in its collaboration with New Mexico State University (NMSU).

The company has established a certification curriculum for Advanced TeleCare Care Coaches, preparing graduates for roles in virtual care operations and remote patient engagement.

This aligned educational pathway fosters a direct connection between academic training and real-world healthcare applications.

As the company continues to grow, it remains focused on integrating advanced healthcare engineering with structured certification pathways.

This strategy demonstrates that competitive AI and health technology infrastructure can be developed and scaled from Las Cruces.

The expansion of Electronic Caregiver is set to redefine the healthcare landscape in Southern New Mexico, positioning Las Cruces as a vital national AI healthcare infrastructure hub.

By fostering innovation and creating employment opportunities, the company is paving the way for a new era in healthcare delivery that leverages technology to meet the needs of patients across the United States.

As Electronic Caregiver continues to build its operations, the region stands to benefit from enhanced healthcare services, job creation, and a strengthened economy, marking a pivotal moment for both the company and the community it serves.

Electronic Caregiver Enhances Las Cruces as National AI Healthcare Hub

electronic-caregiver-enhances-las-cruces-as-national-ai-healthcare-hub

The European Medicines Agency has recommended the approval of Moderna's mCombriax, a combined vaccine targeting both COVID-19 and influenza. This decision aims to simplify vaccination efforts and improve health outcomes for older adults across the European Union.

## EMA Recommends Approval for Moderna's Combined Flu and COVID Vaccine

The European Medicines Agency (EMA) has announced its recommendation for marketing authorization of mCombriax, Moderna's innovative combined mRNA vaccine designed to protect older adults against both COVID-19 and influenza.

This endorsement was made by the EMA's Committee for Medicinal Products for Human Use, following a comprehensive review of data from a phase 3 trial that involved 8,000 participants aged 50 and older.

The trial results indicated that participants who received mCombriax exhibited immune responses that were non-inferior to those who received either Moderna's licensed COVID-19 vaccine, Spikevax, or authorized flu vaccines, including Fluzone and Fluarix.

If the European Commission accepts the EMA's recommendation, mCombriax will become available across the European Union, providing individuals with the option of receiving a single shot to protect against both illnesses.

In a statement, Moderna's CEO, Stephane Bancel, emphasized the significance of this recommendation, calling it an important milestone for respiratory virus vaccination and for the company itself.

Bancel noted that combination vaccines have the potential to simplify vaccination processes, which could lead to improved health outcomes for the population.

The EMA highlighted that national authorities will ultimately determine which vaccines to deploy and how they will be recommended to the public, taking into account the specific health situations in their respective countries.

This flexibility allows countries to tailor their vaccination campaigns based on local health needs and population demographics.

The recommendation comes at a time when the ongoing threat of COVID-19 and seasonal influenza continues to pose significant public health challenges, particularly for vulnerable groups such as older adults.

Vaccination remains a critical tool in preventing severe disease and reducing mortality associated with these viruses.

The combined vaccine is particularly relevant given the lessons learned during the COVID-19 pandemic.

Vaccines have played a crucial role in reducing the spread of the virus and the severity of the disease, with estimates suggesting that COVID-19 vaccines saved at least 14.4 million lives globally in 2021 alone.

The introduction of mCombriax could enhance vaccination coverage by streamlining the administration process for two significant respiratory illnesses.

Moderna had previously submitted a Biologic License Application to the US Food and Drug Administration (FDA) for mCombriax in 2024.

However, the application was withdrawn in May 2025 after the FDA requested additional data.

The EMA's current recommendation may serve as a catalyst for future approvals in other regions as well.

Overall, the EMA's positive assessment of mCombriax underscores the ongoing commitment to advancing public health through innovative vaccine development and the potential for combination vaccines to address multiple health threats simultaneously.

As the situation evolves, continued monitoring and research will be essential to ensure the safety and efficacy of this new vaccine option in real-world settings.

The approval of mCombriax not only represents a potential advancement in the fight against respiratory infections but also signals a broader shift towards more integrated vaccination strategies that could help manage public health more effectively in the years to come.

EMA Recommends Approval for Moderna's Combined Flu and COVID Vaccine

ema-recommends-approval-for-moderna-s-combined-flu-and-covid-vaccine

The Trump Administration has initiated significant changes in healthcare policy that impact New York's health landscape. Key reforms focus on interoperability and the integration of technology in health services, aiming to enhance patient care while navigating the complexities of federal funding and regulation.

## Navigating Trump Administration's Health Care Policy in New York

The Trump Administration has taken bold steps toward transforming healthcare in the United States, with a particular focus on interoperability and technology integration.

These changes are crucial for New York as policymakers navigate the evolving healthcare landscape.

At a recent White House event, the Administration unveiled a collaborative initiative with major tech companies, including Amazon and Apple, aimed at creating a modernized digital health ecosystem.

This initiative, dubbed the Health Tech Ecosystem, seeks to improve patient outcomes by facilitating seamless data sharing between patients and healthcare providers, enhancing user-friendly applications for managing health information, and ultimately empowering patients to take control of their healthcare decisions.

The initiative aligns with President Trump's broader vision outlined in his Executive Order on government efficiency, which aims to streamline healthcare services while reducing costs.

The Department of Health and Human Services (HHS) has committed to significant reforms that include cutting the workforce by approximately 10,000 employees, which is expected to save taxpayers $1.8 billion annually.

As part of these reforms, the HHS plans to consolidate its divisions into a more efficient structure that includes the newly established Administration for a Healthy America (AHA).

This entity will unify various health agencies, enabling better coordination and resource allocation for programs focusing on maternal and child health, mental health, and chronic disease prevention, which are particularly relevant to New York's diverse population.

Despite these advancements, the state faces challenges related to federal funding cuts and compliance pressures.

The Trump Administration has been known to withhold federal funding from institutions that do not align with its policy objectives.

This tactic was evident when the administration targeted Columbia University, withholding $400 million over alleged failures to address antisemitism on campus.

This has raised concerns among academic institutions regarding their funding stability, particularly in healthcare research, which is vital for innovation and effective patient care.

Amid the shifting political climate, healthcare stakeholders in New York are advised to remain vigilant and proactive.

Legal and policy experts emphasize the importance of understanding the new regulatory environment.

Firms like Alston & Bird are positioned to guide healthcare clients through the complexities of navigating these changes, leveraging their connections and expertise in health policy advocacy.

Moreover, as New York implements its health policies in response to federal reforms, local leaders must prioritize strategies that align with both state and federal guidelines while serving the needs of their communities.

This includes embracing technology to enhance patient engagement and outcomes, as well as ensuring that health services remain accessible and equitable.

The integration of technology in healthcare services is not only a priority for the Trump Administration but is also viewed as essential for modernizing New York's healthcare system.

With advancements in digital health tools, patients will gain better access to their medical records and have more control over their health decisions, thereby improving overall healthcare quality.

In conclusion, as New York navigates the complexities of healthcare policy under the Trump Administration, a focus on collaboration between the private sector and government agencies will be crucial.

By leveraging technological advancements and advocating for necessary funding and support, state leaders can work to ensure that New York's healthcare system evolves effectively to meet the needs of its residents while aligning with federal initiatives.

Navigating Trump Administration's Health Care Policy in New York

navigating-trump-administration-s-health-care-policy-in-new-york

The University of Cincinnati's College of Medicine has been awarded a grant exceeding $1 million to integrate artificial intelligence into medical education. This initiative aims to enhance physician training by providing personalized learning experiences through AI technologies.

## UC Receives Over $1 Million Grant for AI in Medical Training

The University of Cincinnati's College of Medicine has received a significant grant valued at over $1 million to incorporate artificial intelligence (AI) into its medical education programs.

This funding aims to address a critical challenge in medical training: the lack of sufficient, high-quality feedback for medical trainees during clinical practice.

The grant will allow the college to utilize advanced technologies such as AI glasses and smartphones to enhance the training environment for medical students.

These tools are intended to capture real-time interactions, providing valuable insights that can improve student performance and patient care skills.

Ivy Xue, a medical student at UC, expressed enthusiasm for the initiative, emphasizing her interest in the intersection of AI and medicine.

She believes that the use of AI glasses will significantly enhance the learning experience.

"Being able to get more reps in and get more individualized feedback, in real-time, I think it will be a really great improvement," Xue noted.

The data collected from these AI devices will enable trainees to refine their patient interactions and improve their diagnostic reasoning.

The integration of AI into the curriculum is expected to facilitate a more personalized learning experience, allowing the system to adapt based on individual student needs.

For instance, if a student consistently overlooks certain aspects of patient history, the AI can provide targeted scenarios to help them improve.

Laurah Turner, the associate dean of artificial intelligence and educational informatics at the university, highlighted the competitive nature of securing this grant.

The American Medical Association selected only 11 recipients from nearly 200 applicants, underscoring the significance of this funding for the university.

In addition to enhancing feedback mechanisms, the program aims to familiarize students with cutting-edge technology that is increasingly prevalent in healthcare settings.

As AI continues to transform the medical field, training the next generation of physicians to effectively use these tools will be crucial.

Xue described the incorporation of AI in medical training as a glimpse into the future of healthcare.

"It does feel sort of like this is the future that we've been seeing on television," she remarked, expressing her excitement about the potential of AI to revolutionize medical education and patient care.

The University of Cincinnati's initiative is part of a broader trend toward integrating technology into medical training, reflecting the industry's shift toward embracing innovative solutions for improving healthcare education.

As AI continues to evolve, its applications in medicine are expected to expand, potentially transforming how future physicians are trained and how patient care is delivered.

This grant represents a significant step forward in medical education, demonstrating the University of Cincinnati's commitment to leveraging technology to enhance training and improve healthcare outcomes.

By utilizing AI, the college aims to prepare its students for the complexities of modern medical practice, ultimately benefiting both trainees and patients alike.

As the program unfolds, it will be closely monitored to assess its impact on medical training and the effectiveness of AI as a learning tool.

The hope is that this initiative will serve as a model for other institutions seeking to integrate advanced technologies into their educational frameworks, paving the way for a new era in medical education.

The integration of AI into medical training at UC is indicative of a larger movement in healthcare education, where technology plays a pivotal role in shaping the future of physician training.

With ongoing advancements in AI, the potential for enhanced learning experiences and improved patient care continues to grow.

UC Receives Over $1 Million Grant for AI in Medical Training

uc-receives-over-1-million-grant-for-ai-in-medical-training

The USF Health Morsani College of Medicine has achieved national recognition with two departments ranking in the Top 10 for NIH funding. This accomplishment reflects the college's commitment to cutting-edge research and its role in advancing medical science.

## USF Health Morsani College of Medicine Achieves Top 10 NIH Rankings

The USF Health Morsani College of Medicine (MCOM) has reached a significant milestone, with two of its departments now ranked among the Top 10 in the nation for National Institutes of Health (NIH) funding.

The Department of Otolaryngology-Head and Neck Surgery placed sixth overall and second among public universities, while the Department of Molecular Pharmacology & Physiology secured the tenth position in the latest rankings from the Blue Ridge Institute for Medical Research.

This year's rankings highlight impressive progress across both basic science and clinical research, with four departments newly entering the Top 50: Molecular Medicine (Biochemistry), Orthopaedics, Otolaryngology, and Surgery.

This upward trajectory underscores the robust research enterprise at MCOM and reflects the dedication of its faculty members, as noted by Charles J.

Lockwood, MD, MHCM, the executive vice president of USF Health and dean of the college.

Lockwood emphasized that the exceptional work of the college's scientists is crucial for advancing research discoveries and developing innovative treatments for patients in Florida and beyond.

Key to this achievement has been the college's ongoing investment in faculty recruitment, research infrastructure, and collaborative scientific endeavors.

Matt Anderson, PhD, associate vice president for research administration at USF Health, stated that these rankings are a testament to the quality and competitiveness of their research programs.

He highlighted that the college's investigators are addressing complex health challenges across various disciplines, leading to meaningful advancements in human health.

The Morsani College of Medicine's recent achievements build on its recognition by US News & World Report as Florida's top-ranked medical school and one of only 16 medical schools nationally awarded a Tier 1 ranking, indicating the highest level of excellence in medical education and research.

This recognition is part of a broader trend of increasing research funding for the University of South Florida, which is a member of the Association of American Universities, an acknowledgment of its status as a leading national research institution.

Moreover, the college is home to the world's top NIH-funded principal investigator, Jeffrey Krischer, PhD, who has dedicated his career to diabetes research and understanding autoimmunity.

Dr Krischer's NIH-funded research totals over $64 million, making him the highest-funded principal investigator globally.

His efforts are supported by the Health Informatics Institute, which coordinates significant research data related to type 1 diabetes and rare diseases, further cementing the college's role in pioneering medical research.

The Morsani College of Medicine, in collaboration with its primary teaching hospital, Tampa General Hospital, serves as an integrated academic medical center for the region, providing critical healthcare services and fostering economic opportunity and innovation.

The college emphasizes a commitment to clinical excellence, education, and research, aiming to improve patient care and outcomes while nurturing the next generation of leaders in academic medicine.

In conclusion, the USF Health Morsani College of Medicine's recent Top 10 rankings for NIH funding reflect a strong commitment to research excellence and innovation.

The college's strategic investments in faculty and infrastructure, combined with its collaborative approach to addressing complex health challenges, position it as a leader in advancing medical science and improving health outcomes in the community and beyond.

USF Health Morsani College of Medicine Achieves Top 10 NIH Rankings

usf-health-morsani-college-of-medicine-achieves-top-10-nih-rankings

A recent study published in Nature Medicine suggests that cancer treatment may be more effective when administered in the morning. Researchers are conducting further investigations to understand the underlying mechanisms and implications of this timing on patient outcomes.

## Nature Medicine to Investigate Morning Cancer Treatment Effectiveness

A new study published in Nature Medicine has revealed that the timing of cancer treatment may significantly influence its effectiveness, with findings suggesting that morning treatments could yield better outcomes for patients.

This revelation has prompted further investigations by researchers to delve deeper into the mechanisms behind this timing effect and its potential implications for clinical practices.

The study, which evaluated various cancer therapies, found that patients receiving treatment in the morning exhibited improved responses compared to those treated later in the day.

This aligns with previous research indicating that the body's biological rhythms could play a crucial role in how medications are metabolized and their subsequent effectiveness.

The findings are particularly significant as they challenge the traditional one-size-fits-all approach to cancer treatment schedules.

By tailoring treatment times to align with the body's circadian rhythms, healthcare providers may enhance therapeutic efficacy and improve patient outcomes.

Dr Benjamin Musher, a lead researcher involved in the study, emphasized the importance of understanding the biological underpinnings of these findings.

"We are exploring how the body's internal clock interacts with cancer therapies, which could lead to innovative treatment protocols that optimize patient care," he stated.

The implications of this research extend beyond mere scheduling; they also raise questions about how treatment timing could affect side effects and overall patient quality of life.

For instance, if morning treatments are shown to be less taxing on the body, patients may experience fewer adverse effects, thereby enhancing their overall treatment experience.

As the investigation continues, researchers at Baylor College of Medicine are focusing on the mechanisms that govern the interaction between the body’s biological clock and cancer therapies.

This includes studying the levels of certain proteins and hormones that fluctuate throughout the day and how these fluctuations might influence the effectiveness of medications.

The research community is particularly interested in how this knowledge can be translated into practical applications.

If confirmed, these findings could lead to personalized cancer treatment plans that consider not just the type of cancer and the specific therapeutic agents used but also the optimal timing for administration.

In addition to the immediate implications for cancer treatment, this study could also pave the way for broader applications in other areas of medicine.

Understanding the role of circadian rhythms may enhance treatment strategies for various conditions beyond cancer, potentially revolutionizing how healthcare providers approach medication administration.

As the healthcare landscape continues to evolve with new research and innovations, the findings from this study underscore the necessity for ongoing investigations into the complexities of treatment timing.

Future studies will be crucial in validating these findings and determining how they can be implemented effectively in clinical settings.

In conclusion, the research highlighted in Nature Medicine opens new avenues for enhancing cancer treatment efficacy through timing.

As investigations proceed, the hope is to incorporate these insights into practice, ultimately improving outcomes for cancer patients and setting a precedent for future medical research.

Nature Medicine to Investigate Morning Cancer Treatment Effectiveness

nature-medicine-to-investigate-morning-cancer-treatment-effectiveness

The FDA has appointed Rick Abramson, a former AI executive, as the new director of its Digital Health Center of Excellence. This move aims to enhance the agency's focus on the regulation of AI technologies in healthcare, marking a significant step in the evolution of digital health regulations.

## FDA Appoints AI Executive Rick Abramson to Lead Digital Health Center

The Food and Drug Administration (FDA) has appointed Rick Abramson as the new director of its Digital Health Center of Excellence.

Abramson previously served as a chief medical officer at Harrison.ai, a company known for developing artificial intelligence products aimed at interpreting radiological images.

His appointment is part of the FDA's broader strategy to navigate the complexities of regulating AI technologies within healthcare.

Abramson's move to lead the Digital Health Center comes at a critical time, as the FDA has been reassessing its regulatory framework concerning AI products.

Over the past year, the agency has indicated a willingness to relax regulations surrounding AI tools that assist clinicians in decision-making.

This shift is seen as a response to the rapid advancements in technology and the need for regulations to keep pace with innovation.

Since last summer, Abramson has been serving as a senior adviser in the FDA commissioner's office, where he has played a significant role in shaping the agency's strategy on digital health initiatives.

His involvement in promoting a softer regulatory approach for AI products aligns with the FDA's goal to ensure that digital health technologies can be utilized effectively while maintaining patient safety.

The Digital Health Center of Excellence, which operates within the FDA’s Center for Devices and Radiological Health, was established to ensure that healthcare delivery incorporates technology safely and effectively.

The center focuses on evaluating new technologies, developing policies, and fostering strategic partnerships.

As the new director, Abramson will be responsible for leading these efforts and addressing the growing demands for efficient regulatory processes in the face of rapid technological advancement.

In recent discussions, FDA officials acknowledged criticisms that their regulatory processes have not kept pace with the fast-evolving digital health landscape.

The contrast in speed between the private sector, where apps can be updated in real-time, and the FDA's methodical review process has been a point of contention.

Brendan O'Leary, deputy director at the center, highlighted that consumer expectations for timely updates on health products pose challenges for the FDA's existing framework.

The FDA's digital health office was first launched in 2020 with the objective of enhancing the integration of digital health technologies into the US healthcare system, including mobile health devices, software as a medical device, and wearables.

As Abramson takes the helm, there is significant anticipation regarding how his expertise in AI can influence the FDA's regulatory approach and its alignment with ongoing technological advancements.

The appointment of Abramson marks a continuation of the FDA's trend of incorporating leaders with technology backgrounds into key positions.

Previous leaders, such as Troy Tazbaz, have also been brought in to guide the agency's digital health initiatives.

This strategic move underscores the need for regulatory bodies to adapt to the evolving nature of healthcare technology.

As the FDA continues to refine its approach to digital health, Abramson's leadership is expected to play a pivotal role in shaping the future of AI regulation in healthcare, ensuring that innovations can be effectively harnessed to improve patient outcomes while safeguarding public health.

The agency's focus on AI also aligns with broader national goals aimed at enhancing the quality of healthcare delivery through advanced technologies, further underscoring the significance of this appointment in the landscape of US health policy.

With Abramson at the forefront, the FDA is poised to navigate the challenges and opportunities presented by AI in healthcare, potentially leading to more streamlined regulatory processes and improved integration of innovative health technologies in the clinical setting.

The coming months will be crucial in determining how these changes will unfold under his leadership and what implications they will have for both healthcare providers and patients alike.

FDA Appoints AI Executive Rick Abramson to Lead Digital Health Center

fda-appoints-ai-executive-rick-abramson-to-lead-digital-health-center

Flu vaccination policies significantly impact both public health and economic productivity. Increased vaccination coverage among healthcare workers can reduce absenteeism and enhance workforce productivity, leading to higher tax revenues and overall economic benefits.

## The Economic Implications of Flu Vaccine Policies

Flu vaccination policies play a crucial role in shaping public health outcomes and have significant economic implications.

The relationship between vaccination rates among healthcare workers (HCWs) and productivity underscores the importance of flu vaccination in maintaining a healthy workforce.

Increasing flu vaccination rates among HCWs can markedly improve productivity.

A study indicated that vaccinated HCWs experience lower productivity losses compared to their unvaccinated counterparts.

Specifically, the difference in per capita productivity loss between vaccinated and unvaccinated HCWs was approximately €220, which translates to significant cumulative savings when scaled across a larger workforce.

Moreover, the economic burden of influenza extends beyond health impacts, affecting societal productivity.

Globally, the vaccination coverage among HCWs remains suboptimal, with rates varying widely; for instance, some regions report vaccination rates as low as 15.6% while others achieve around 70% coverage.

This inconsistency reveals a missed opportunity for improving workplace productivity and reducing the economic burden associated with seasonal influenza.

In Italy, a comprehensive analysis demonstrated that an influenza vaccination program for HCWs could lead to reduced indirect costs associated with productivity losses, amounting to nearly €4.5 million over five years, alongside an increase in tax revenues of approximately €327,000.

This model emphasizes the fiscal impact of vaccination while supporting the argument for policies that favor increased vaccination coverage.

The economic rationale for flu vaccinations extends to the broader implications of pandemic preparedness.

Historical data indicates that pandemics, particularly those caused by influenza, can lead to substantial economic disruptions.

For example, the COVID-19 pandemic demonstrated how public health crises could result in significant economic downturns, with GDP in the US experiencing an 8% drop in the early months of the pandemic.

Effective vaccination policies can mitigate these risks by ensuring a healthier population capable of maintaining economic productivity.

Vaccination reduces morbidity and mortality associated with the flu, thereby decreasing healthcare costs and improving workforce participation rates.

Furthermore, the societal benefits of vaccination extend to reducing absenteeism in schools and workplaces, which is critical for maintaining economic stability.

Studies have shown that children’s school absences due to flu-like illnesses can create secondary economic impacts on parents who often miss work to care for sick children.

The need for robust flu vaccination policies is further underscored by the social costs associated with lower vaccination rates.

A significant portion of HCWs report working despite having flu-like symptoms, a phenomenon known as presenteeism, which can exacerbate the spread of influenza and create a vicious cycle of illness and productivity loss.

In conclusion, flu vaccine policies are not merely a health issue; they are deeply intertwined with economic outcomes.

Effective vaccination programs can lead to increased productivity, reduced absenteeism, and higher tax revenues, illustrating that public health initiatives can also serve as economic strategies.

Policymakers should adopt a comprehensive approach that values both health and economic outcomes to foster a resilient workforce capable of withstanding public health challenges.

The ongoing discourse surrounding vaccination policies, particularly in the context of the COVID-19 pandemic, highlights the necessity for continued investment in public health infrastructure.

This investment will not only prepare us for future pandemics but will also ensure ongoing economic stability and growth.

Topic

Medicine

Recent articles:

EMA Recommends Approval for Moderna's Combined Flu and COVID Vaccine

Navigating Trump Administration's Health Care Policy in New York

UC Receives Over $1 Million Grant for AI in Medical Training

USF Health Morsani College of Medicine Achieves Top 10 NIH Rankings

Nature Medicine to Investigate Morning Cancer Treatment Effectiveness

FDA Appoints AI Executive Rick Abramson to Lead Digital Health Center

The Economic Implications of Flu Vaccine Policies

Moderna's FDA Review Offers Hope Amid Political Challenges

Health Officials Urge Measles Vaccine Checks Amid Rising Cases

Disc Medicine Plans Next Steps After FDA CRL for Bitopertin

Ex-Google Exec Warns: Law and Medicine Degrees Might Be Obsolete

AI Tools Like DeepSeek Revolutionizing Youth Mental Health in China

Ex-Google Exec Claims Law and Medicine Degrees May Be Obsolete

Lessons from Past U.S. Global Health Agreements Under Trump

Ex-Google Exec Warns: Law and Medicine Degrees May Soon Be Obsolete

Experts Warn HHS Vaccine Policy Changes Violate Law and Endanger Health

Hims & Hers Stock Plummets After FDA Targets Compounded GLP-1s

Former FDA Chief Critiques HHS for Policy-Based Evidence Approach

CDC Health Alerts Drop Leaves Doctors 'Flying Blind'